{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:35:27Z","timestamp":1783726527846,"version":"3.55.0"},"reference-count":65,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Skin and soft tissue infections (SSTIs) are associated with significant morbidity and healthcare costs, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is a preferred antimicrobial therapy for the management of complicated SSTIs (cSSTIs) caused by MRSA, with linezolid and daptomycin regarded as alternative therapeutic options. Due to the increased rates of antimicrobial resistance in MRSA, several new antibiotics with activity against MRSA have been recently introduced in clinical practice, including ceftobiprole, dalbavancin, and tedizolid. We evaluated the in vitro activities of the aforementioned antibiotics against 124 clinical isolates of MRSA obtained from consecutive patients with SSTIs during the study period (2020\u20132022). Minimum inhibitory concentrations (MICs) for vancomycin, daptomycin, ceftobiprole, dalbavancin, linezolid and tedizolid were evaluated by the MIC Test Strip using Liofilchem strips. We found that when compared to the in vitro activity of vancomycin (MIC90 = 2 \u03bcg\/mL), dalbavancin possessed the lowest MIC90 (MIC90 = 0.094 \u03bcg\/mL), followed by tedizolid (MIC90 = 0.38 \u03bcg\/mL), linezolid, ceftobiprole, and daptomycin (MIC90 = 1 \u03bcg\/mL). Dalbavancin demonstrated significantly lower MIC50 and MIC90 values compared to vancomycin (0.064 vs. 1 and 0.094 vs. 2, respectively). Tedizolid exhibited an almost threefold greater level of in vitro activity than linezolid, and also had superior in vitro activity compared to ceftobiprole, daptomycin and vancomycin. Multidrug-resistant (MDR) phenotypes were detected among 71.8% of the isolates. In conclusion, ceftobiprole, dalbavancin and tedizolid exhibited potent activity against MRSA and are promising antimicrobials in the management of SSTIs caused by MRSA.<\/jats:p>","DOI":"10.3390\/antibiotics12050900","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:49:51Z","timestamp":1683888591000},"page":"900","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-1732","authenticated-orcid":false,"given":"Sofia","family":"Maraki","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, PC 71110 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Eirini","family":"Mavromanolaki","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Crete, PC 71003 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Stafylaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, PC 71110 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Iliaki-Giannakoudaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, PC 71110 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hamilos","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, PC 71110 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","article-title":"Epidemiology and microbiology of skin and soft tissue infections","volume":"29","author":"Esposito","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ray, G.T., Suaya, J.A., and Baxter, R. (2013). Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: A retrospective population-based study. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-252"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QCO.0000000000000527","article-title":"What\u02bcs new in the epidemiology of skin and soft tissue infections in 2018?","volume":"32","author":"Poulakou","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_4","unstructured":"US Food and Drug Administration (2023, March 25). Guidance for Industry. Acute Bacterial Skin and Skin-Structure Infections: Developing Drugs for Treatment. Guidance for Industry, Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceCompli-anceRegulatoryInformation\/Guidances\/UCM071185.pdf."},{"key":"ref_5","unstructured":"European Center for Disease and Prevention Control (2023, March 10). Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Long-Term Care Facilities 2016\u20132017. Stockholm, Sweden. ECDC 2023. Available online: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use2016-2017.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1742-1241.1998.tb08909.x","article-title":"Skin and soft tissue infections: Development of a collaborative management plan between community and hospital care","volume":"52","author":"Nathwani","year":"1998","journal-title":"Int. J. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/sur.2005.6.283","article-title":"Antimicrobial Management of Complicated Skin and Skin Structure Infections in the Era of Emerging Resistance","volume":"6","author":"Lee","year":"2005","journal-title":"Surg. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ioannou, P., Maraki, S., Koumaki, D., Manios, G.A., Koumaki, V., Kassotakis, D., Zacharopoulos, G.V., Kofteridis, D.P., Manios, A., and de Bree, E. (2023). A Six-Year Retrospective Study of Microbiological Characteristics and Antimicrobial Resistance in Specimens from a Tertiary Hospital\u2019s Surgical Ward. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030490"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/520731","article-title":"Severe Surgical Site Infection in Community Hospitals: Epidemiology, Key Procedures, and the Changing Prevalence of Methicillin-Resistant Staphylococcus aureus","volume":"28","author":"Anderson","year":"2007","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1017\/S0950268817001716","article-title":"The rise of methicillin resistant Staphylococcus aureus: Now the dominant cause of skin and soft tissue infection in Central Australia","volume":"145","author":"Macmorran","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2012.05.014","article-title":"In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008\u20132009","volume":"40","author":"Morrissey","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diagmicrobio.2013.02.020","article-title":"Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus","volume":"76","author":"Ray","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","volume":"4","year":"2017","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E377","DOI":"10.1111\/1469-0691.12235","article-title":"Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010\u20132011): Assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study","volume":"19","author":"Garau","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/526444","article-title":"Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Hospitalized Patients with Complicated Skin and Skin-Structure Infections","volume":"29","author":"Edelsberg","year":"2008","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3122\/jabfm.2013.05.120247","article-title":"Treatment Failure and Costs in Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study","volume":"26","author":"Labreche","year":"2013","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3122\/jabfm.2011.05.110073","article-title":"Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study","volume":"24","author":"Forcade","year":"2011","journal-title":"J. Am. Board Fam. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12941-022-00529-z","article-title":"Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis","volume":"21","author":"Liu","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"iii45","DOI":"10.1093\/jac\/dkr098","article-title":"Review of ceftaroline fosamil microbiology: Integrated FOCUS studies","volume":"66","author":"Critchley","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2008.12.012","article-title":"Ceftobiprole: A novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)","volume":"34","author":"Barbour","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-015-0060-3","article-title":"Tedizolid Phosphate: A Next-Generation Oxazolidinone","volume":"4","author":"Rybak","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14787210.2018.1489721","article-title":"Delafloxacin: A novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa","volume":"16","author":"Ocheretyaner","year":"2018","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2018.11.013","article-title":"Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America","volume":"17","author":"Sader","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/emermed-2013-203373","article-title":"Prevalence and molecular characteristics of methicillin-resistant Staphylococcus aureus among skin and soft tissue infections in an emergency department in Guyana","volume":"32","author":"Dozois","year":"2014","journal-title":"Emerg. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, X., Chen, Y., Gao, W., Ouyang, W., Wei, J., and Wen, Z. (2016). Epidemiology and outcomes of complicated skin and soft tissue infections among inpatients in Southern China from 2008 to 2013. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149960"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1128\/JCM.00134-12","article-title":"Trends and Characteristics of Culture-Confirmed Staphylococcus aureus Infections in a Large U.S. Integrated Health Care Organization","volume":"50","author":"Ray","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/AAC.01244-06","article-title":"Treatment and Outcomes of Infections by Methicillin-Resistant Staphylococcus aureus at an Ambulatory Clinic","volume":"51","author":"Szumowski","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/JCM.05817-11","article-title":"Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients","volume":"50","author":"Zervos","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/jac\/dkw431","article-title":"MRSA infections among patients in the emergency department: A European multicentre study","volume":"72","author":"Bouchiat","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Stefanaki, C., Ieronymaki, A., Matoula, T., Caroni, C., Polythodoraki, E., Chryssou, S.-E., Kontochristopoulos, G., and Antoniou, C. (2017). Six-Year Retrospective Review of Hospital Data on Antimicrobial Resistance Profile of Staphylococcus aureus Isolated from Skin Infections from a Single Institution in Greece. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040039"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijantimicag.2019.08.020","article-title":"Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen","volume":"54","author":"Nodaras","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cmdc.202000677","article-title":"Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm-Associated Infections","volume":"16","author":"Cascioferro","year":"2020","journal-title":"Chemmedchem"},{"key":"ref_38","unstructured":"World Health Organization (2017). Priorization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis, World Health Organization."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/jac\/dkx200","article-title":"Emerging multidrug resistance in community-associated Staphylococcus aureus involved in skin and soft tissue infections and nasal colonization","volume":"72","author":"Lee","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00019053-200725090-00004","article-title":"Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and analysis of the literature","volume":"25","author":"Shorr","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/422458","article-title":"Staphylococcus aureus with Reduced Susceptibility to Vancomycin","volume":"39","author":"Cosgrove","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3410\/M4-4","article-title":"Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (\u2018the MIC Creep\u2019): Implications for therapy","volume":"4","author":"Dhand","year":"2012","journal-title":"F1000 Med. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.ijid.2012.08.005","article-title":"High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: A meta-analysis","volume":"17","author":"Jacob","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02566-19","DOI":"10.1128\/AAC.02566-19","article-title":"Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018","volume":"64","author":"Flamm","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jgar.2022.05.001","article-title":"Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories","volume":"29","author":"Hawser","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Dandan, Y., Shi, W., Yang, Y., Yonggui, Z., Zhu, D., Yan, G., and Hu, F. (2022). Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016\u20132018). BMC Microbiol., 22.","DOI":"10.1186\/s12866-022-02699-4"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chen, C.-Y., Chen, W.-C., Lai, C.-C., Shih, T.-P., and Tang, H.-J. (2021). Anti-MRSA Cephalosporin versus Vancomycin-Based Treatment for Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081020"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)","volume":"73","author":"Overcash","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond Vancomycin: The Tail of the Lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diagmicrobio.2014.05.014","article-title":"Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains","volume":"79","author":"Citron","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_52","first-page":"114901","article-title":"In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times","volume":"96","author":"Ceccherini","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e00351-22","DOI":"10.1128\/spectrum.00351-22","article-title":"Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections","volume":"10","author":"Sivori","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_54","first-page":"1477","article-title":"Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: A systematic review and meta-analysis","volume":"20","author":"Nava","year":"2020","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Scutera, S., Sparti, R., Comini, S., Menotti, F., Musso, T., Cuffini, A.M., Allizond, V., and Banche, G. (2023). Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032541"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106746","DOI":"10.1016\/j.ijantimicag.2023.106746","article-title":"REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI","volume":"61","author":"Papavramidis","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3343\/alm.2015.35.5.523","article-title":"In Vitro Activity of Tedizolid Against Gram-Positive Bacteria in Patients With Skin and Skin Structure Infections and Hospital-Acquired Pneumonia: A Korean Multicenter Study","volume":"35","author":"Lee","year":"2015","journal-title":"Ann. Lab. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014Results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7547\/15-218","article-title":"Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non\u2013Lower-Extremity Infections","volume":"107","author":"Joseph","year":"2017","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10096-016-2744-3","article-title":"In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China","volume":"35","author":"Biedenbach","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1089\/mdr.2018.0457","article-title":"Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Staphylococcus aureus: A Systematic Review and Meta-Analysis","volume":"25","author":"Mojtahedi","year":"2019","journal-title":"Microb. Drug Resist."},{"key":"ref_63","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2021). Breakpoint Tables for Interpretation for MICs and Zone Diameters: Version 12.0, Valid from 2022-01-01, EUCAST."},{"key":"ref_64","unstructured":"(2018). CLSI M02; Performance Standards for Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute. [13th ed.]."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/5\/900\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:59Z","timestamp":1760124839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/5\/900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["antibiotics12050900"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12050900","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}